Exablate Model 4000 System
Insightec · Decision date Jan 28, 2026
What did the FDA decide?
FDA records P150038/S043 as a supplement to PMA P150038, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jan 28, 2026.
FDA approval order statement
a change in Exablate 4000 Digital Control and Acquisition board (DCA) testing procedure
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Neurology
- Decision date
- Jan 28, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P150038/S043
- Regulatory pathway
- PMA supplement
- Applicant
- Insightec
- Product code
- POH
- Decision code
- OK30
- Decision date
- Jan 28, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: MR-guided focused ultrasound system.
For the original device and its historical approval scope, see PMA P150038. Subsequent supplements may change the device or its indications.
FDA decision timeline
P150038 · Original PMA
EXABLATE
P150038/S043 received
Application receipt date recorded by FDA.
P150038/S043 · FDA decision
30-Day Notice
P150038/S042 · Related supplement
Exablate Model 4000 Type 1.0 and 1.1 (Exablate Neuro; Exablate Prime)
P150038/S044 · Related supplement
Exablate Model 4000 System
Timeline entries are records held by MedtechLedger for P150038. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P150038
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Insightec
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 5 Nahum Heth St., Tirat Carmel, 39120
Sources and methodology
- Original FDA record: P150038/S043
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


